Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 through its next stage of development.

International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

PacificHealth Laboratories, Inc. company was founded in 1995 and is based in Matawan, New Jersey. PacificHealth Laboratories, Inc. engages in the development, marketing, and sale of protein-based nutritional products for appetite regulation. It principally focuses on sports performance, weight loss, and management of Type II diabetes. The company offers ENDUROX R4, a recovery drink; ACCELERADE, a sports drink; ACCEL GEL, an energy gel; and ENDUROX EXCEL, a dietary supplement. PacificHealth Laboratories sells its products through retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors.

Synteract, Inc. company has overseen hundreds of projects for clients that include biotechnology and pharmaceutical companies, as well as medical device makers. On top of research services, Synteract offers clients proprietary and customizable software solutions for managing research and trial data. The company's expertise covers a wide range of health issues, including oncology, HIV/AIDS, ophthalmology, and gastrointestinal disorders. Founded in 1995, Synteract maintains offices in San Diego, Philadelphia, and North Carolina.

Protalex, Inc. company was founded in 1999 and is headquartered in New Hope, Pennsylvania. Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. Protalex company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100, is a purified form of the Staphylococcal bacterial protein known as Protein A that has the ability to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are key cells mediating inflammation in certain autoimmune diseases.

Elan Corporation, plc company was founded in 1969 and is headquartered in Dublin, Ireland. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.